Skip to main content
Journal cover image

Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.

Publication ,  Journal Article
Jazwinski, AB; Muir, AJ
Published in: Gastroenterol Clin North Am
September 2011

The HCV viral life cycle provides targets for drug development at virtually every step, and many new drugs aimed at these targets are currently being developed. Clinical practice takes a major step forward this year with the arrival of telaprevir and boceprevir, which will be added to the current standard of care of pegIFNα/RBV. Patients will need to be monitored closely and counseled extensively, and clinicians will need to learn the new response-guided therapy algorithms with these therapies. Although there remains work to be done in the field of HCV, these therapies will allow many more patients the opportunity to eradicate HCV infection.

Duke Scholars

Published In

Gastroenterol Clin North Am

DOI

EISSN

1558-1942

Publication Date

September 2011

Volume

40

Issue

3

Start / End Page

481 / 494

Location

United States

Related Subject Headings

  • Viral Nonstructural Proteins
  • Serine Proteinase Inhibitors
  • Proline
  • Oligopeptides
  • Nucleosides
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Gastroenterology & Hepatology
  • Enzyme Inhibitors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jazwinski, A. B., & Muir, A. J. (2011). Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am, 40(3), 481–494. https://doi.org/10.1016/j.gtc.2011.06.005
Jazwinski, Alison B., and Andrew J. Muir. “Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.Gastroenterol Clin North Am 40, no. 3 (September 2011): 481–94. https://doi.org/10.1016/j.gtc.2011.06.005.
Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am. 2011 Sep;40(3):481–94.
Jazwinski, Alison B., and Andrew J. Muir. “Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.Gastroenterol Clin North Am, vol. 40, no. 3, Sept. 2011, pp. 481–94. Pubmed, doi:10.1016/j.gtc.2011.06.005.
Jazwinski AB, Muir AJ. Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. Gastroenterol Clin North Am. 2011 Sep;40(3):481–494.
Journal cover image

Published In

Gastroenterol Clin North Am

DOI

EISSN

1558-1942

Publication Date

September 2011

Volume

40

Issue

3

Start / End Page

481 / 494

Location

United States

Related Subject Headings

  • Viral Nonstructural Proteins
  • Serine Proteinase Inhibitors
  • Proline
  • Oligopeptides
  • Nucleosides
  • Humans
  • Hepatitis C, Chronic
  • Hepacivirus
  • Gastroenterology & Hepatology
  • Enzyme Inhibitors